Functional factor VIII made with von Willebrand factor at high levels in transgenic milk
Background: Current manufacturing methods for recombinant human factor VIII (rFVIII) within mammalian cell cultures are inefficient, hampering the production of sufficient amounts for affordable, worldwide treatment of hemophilia A. However, rFVIII has been expressed at very high levels by the trans...
Gespeichert in:
Veröffentlicht in: | Journal of thrombosis and haemostasis 2011-11, Vol.9 (11), p.2235-2242 |
---|---|
Hauptverfasser: | , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 2242 |
---|---|
container_issue | 11 |
container_start_page | 2235 |
container_title | Journal of thrombosis and haemostasis |
container_volume | 9 |
creator | PIPE, S. W. MIAO, H. BUTLER, S. P. CALCATERRA, J. VELANDER, W. H. |
description | Background: Current manufacturing methods for recombinant human factor VIII (rFVIII) within mammalian cell cultures are inefficient, hampering the production of sufficient amounts for affordable, worldwide treatment of hemophilia A. However, rFVIII has been expressed at very high levels by the transgenic mammary glands of mice, rabbits, sheep, and pigs. Unfortunately, it is secreted into milk with low specific activity, owing in part to the labile, heterodimeric structure that results from furin processing of its B domain. Objectives: To express biologically active rFVIII in the milk of transgenic mice through targeted bioengineering. Methods: Transgenic mice were made with a mammary‐specific FVIII gene (226/N6) bioengineered for efficient expression and stability, encoding a protein containing a B domain with no furin cleavage sites. 226/N6 was expressed with and without von Willebrand factor (VWF). 226/N6 was evaluated by ELISA, SDS‐PAGE, western blot, and one‐stage and two‐stage clotting assays. The hemostatic activity of immunoaffinity‐enriched 226/N6 was studied in vivo by infusion into hemophilia A knockout mice. Results and conclusions: With or without coexpression of VWF, 226/N6 was secreted into milk as a biologically active single‐chain molecule that retained high specific activity, similar to therapeutic‐grade FVIII. 226/N6 had > 450‐fold higher IU mL−1 than previously reported in cell culture for rFVIII. 226/N6 exhibited similar binding to plasma‐derived VWF as therapeutic‐grade rFVIII, and intravenous infusion of transgenic 226/N6 corrected the bleeding phenotype of hemophilia A mice. This provides proof‐of‐principle for the study of expression of 226/N6 and perhaps other single‐chain bioengineered rFVIIIs in the milk of transgenic livestock. |
doi_str_mv | 10.1111/j.1538-7836.2011.04505.x |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3444248</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1399903081</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5065-a671fd0857cff80824844a5620cc3ce4d48ee0b76df6bf4cdb37c86a753db7d93</originalsourceid><addsrcrecordid>eNqNkc1O3DAUhS1UxF95BeRdu5lwHduJs2ilCpUyCIkNbdWV5djOjKeOQ-PMAG_Ds_BkOMwwopuq3vha57vnXusghAlkJJ3TRUY4FZNS0CLLgZAMGAee3e-gg63w7rWuKN1HhzEuAEjFc9hD-zmp8vSiB-jX-TLowXVBedwoPXT90-OP6XSKW2UsvnPDHK-6gH86723dq2A2FFYDnrvZHHu7sj5iF_CQ5DizwWncOv_7PdptlI_2eHMfoe_nX2_OLiZX19-mZ1-uJppDwSeqKEljQPBSN40AkTPBmOJFDlpTbZlhwlqoy8I0Rd0wbWpaalGoklNTl6aiR-jz2vd2WbfWaBvSIl7e9q5V_YPslJN_K8HN5axbScoYS9OSwYeNQd_9Wdo4yNZFbb1XwXbLKCsgBaMlsER-_CdJaFVVQEGQhIo1qvsuxt4224UIyDFDuZBjPHKMSo4ZypcM5X1qPXn7oW3ja2gJ-LQG7py3D_9tLC9vLsaKPgOUJayf</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1399903081</pqid></control><display><type>article</type><title>Functional factor VIII made with von Willebrand factor at high levels in transgenic milk</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>PIPE, S. W. ; MIAO, H. ; BUTLER, S. P. ; CALCATERRA, J. ; VELANDER, W. H.</creator><creatorcontrib>PIPE, S. W. ; MIAO, H. ; BUTLER, S. P. ; CALCATERRA, J. ; VELANDER, W. H.</creatorcontrib><description>Background: Current manufacturing methods for recombinant human factor VIII (rFVIII) within mammalian cell cultures are inefficient, hampering the production of sufficient amounts for affordable, worldwide treatment of hemophilia A. However, rFVIII has been expressed at very high levels by the transgenic mammary glands of mice, rabbits, sheep, and pigs. Unfortunately, it is secreted into milk with low specific activity, owing in part to the labile, heterodimeric structure that results from furin processing of its B domain. Objectives: To express biologically active rFVIII in the milk of transgenic mice through targeted bioengineering. Methods: Transgenic mice were made with a mammary‐specific FVIII gene (226/N6) bioengineered for efficient expression and stability, encoding a protein containing a B domain with no furin cleavage sites. 226/N6 was expressed with and without von Willebrand factor (VWF). 226/N6 was evaluated by ELISA, SDS‐PAGE, western blot, and one‐stage and two‐stage clotting assays. The hemostatic activity of immunoaffinity‐enriched 226/N6 was studied in vivo by infusion into hemophilia A knockout mice. Results and conclusions: With or without coexpression of VWF, 226/N6 was secreted into milk as a biologically active single‐chain molecule that retained high specific activity, similar to therapeutic‐grade FVIII. 226/N6 had > 450‐fold higher IU mL−1 than previously reported in cell culture for rFVIII. 226/N6 exhibited similar binding to plasma‐derived VWF as therapeutic‐grade rFVIII, and intravenous infusion of transgenic 226/N6 corrected the bleeding phenotype of hemophilia A mice. This provides proof‐of‐principle for the study of expression of 226/N6 and perhaps other single‐chain bioengineered rFVIIIs in the milk of transgenic livestock.</description><identifier>ISSN: 1538-7933</identifier><identifier>ISSN: 1538-7836</identifier><identifier>EISSN: 1538-7836</identifier><identifier>DOI: 10.1111/j.1538-7836.2011.04505.x</identifier><identifier>PMID: 21920013</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Animals ; Bioengineering ; Cells, Cultured ; Factor VIII - biosynthesis ; Factor VIII - genetics ; Factor VIII - therapeutic use ; factor VIII ; hemophilia ; Hemophilia A - drug therapy ; Humans ; mammary gland ; Mice ; Mice, Transgenic ; Milk - chemistry ; Milk - metabolism ; modified B domain ; recombinant protein ; transgenic animal ; von Willebrand factor ; von Willebrand Factor - biosynthesis ; von Willebrand Factor - genetics</subject><ispartof>Journal of thrombosis and haemostasis, 2011-11, Vol.9 (11), p.2235-2242</ispartof><rights>2011 International Society on Thrombosis and Haemostasis</rights><rights>2011 International Society on Thrombosis and Haemostasis.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5065-a671fd0857cff80824844a5620cc3ce4d48ee0b76df6bf4cdb37c86a753db7d93</citedby><cites>FETCH-LOGICAL-c5065-a671fd0857cff80824844a5620cc3ce4d48ee0b76df6bf4cdb37c86a753db7d93</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21920013$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>PIPE, S. W.</creatorcontrib><creatorcontrib>MIAO, H.</creatorcontrib><creatorcontrib>BUTLER, S. P.</creatorcontrib><creatorcontrib>CALCATERRA, J.</creatorcontrib><creatorcontrib>VELANDER, W. H.</creatorcontrib><title>Functional factor VIII made with von Willebrand factor at high levels in transgenic milk</title><title>Journal of thrombosis and haemostasis</title><addtitle>J Thromb Haemost</addtitle><description>Background: Current manufacturing methods for recombinant human factor VIII (rFVIII) within mammalian cell cultures are inefficient, hampering the production of sufficient amounts for affordable, worldwide treatment of hemophilia A. However, rFVIII has been expressed at very high levels by the transgenic mammary glands of mice, rabbits, sheep, and pigs. Unfortunately, it is secreted into milk with low specific activity, owing in part to the labile, heterodimeric structure that results from furin processing of its B domain. Objectives: To express biologically active rFVIII in the milk of transgenic mice through targeted bioengineering. Methods: Transgenic mice were made with a mammary‐specific FVIII gene (226/N6) bioengineered for efficient expression and stability, encoding a protein containing a B domain with no furin cleavage sites. 226/N6 was expressed with and without von Willebrand factor (VWF). 226/N6 was evaluated by ELISA, SDS‐PAGE, western blot, and one‐stage and two‐stage clotting assays. The hemostatic activity of immunoaffinity‐enriched 226/N6 was studied in vivo by infusion into hemophilia A knockout mice. Results and conclusions: With or without coexpression of VWF, 226/N6 was secreted into milk as a biologically active single‐chain molecule that retained high specific activity, similar to therapeutic‐grade FVIII. 226/N6 had > 450‐fold higher IU mL−1 than previously reported in cell culture for rFVIII. 226/N6 exhibited similar binding to plasma‐derived VWF as therapeutic‐grade rFVIII, and intravenous infusion of transgenic 226/N6 corrected the bleeding phenotype of hemophilia A mice. This provides proof‐of‐principle for the study of expression of 226/N6 and perhaps other single‐chain bioengineered rFVIIIs in the milk of transgenic livestock.</description><subject>Animals</subject><subject>Bioengineering</subject><subject>Cells, Cultured</subject><subject>Factor VIII - biosynthesis</subject><subject>Factor VIII - genetics</subject><subject>Factor VIII - therapeutic use</subject><subject>factor VIII</subject><subject>hemophilia</subject><subject>Hemophilia A - drug therapy</subject><subject>Humans</subject><subject>mammary gland</subject><subject>Mice</subject><subject>Mice, Transgenic</subject><subject>Milk - chemistry</subject><subject>Milk - metabolism</subject><subject>modified B domain</subject><subject>recombinant protein</subject><subject>transgenic animal</subject><subject>von Willebrand factor</subject><subject>von Willebrand Factor - biosynthesis</subject><subject>von Willebrand Factor - genetics</subject><issn>1538-7933</issn><issn>1538-7836</issn><issn>1538-7836</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkc1O3DAUhS1UxF95BeRdu5lwHduJs2ilCpUyCIkNbdWV5djOjKeOQ-PMAG_Ds_BkOMwwopuq3vha57vnXusghAlkJJ3TRUY4FZNS0CLLgZAMGAee3e-gg63w7rWuKN1HhzEuAEjFc9hD-zmp8vSiB-jX-TLowXVBedwoPXT90-OP6XSKW2UsvnPDHK-6gH86723dq2A2FFYDnrvZHHu7sj5iF_CQ5DizwWncOv_7PdptlI_2eHMfoe_nX2_OLiZX19-mZ1-uJppDwSeqKEljQPBSN40AkTPBmOJFDlpTbZlhwlqoy8I0Rd0wbWpaalGoklNTl6aiR-jz2vd2WbfWaBvSIl7e9q5V_YPslJN_K8HN5axbScoYS9OSwYeNQd_9Wdo4yNZFbb1XwXbLKCsgBaMlsER-_CdJaFVVQEGQhIo1qvsuxt4224UIyDFDuZBjPHKMSo4ZypcM5X1qPXn7oW3ja2gJ-LQG7py3D_9tLC9vLsaKPgOUJayf</recordid><startdate>201111</startdate><enddate>201111</enddate><creator>PIPE, S. W.</creator><creator>MIAO, H.</creator><creator>BUTLER, S. P.</creator><creator>CALCATERRA, J.</creator><creator>VELANDER, W. H.</creator><general>Blackwell Publishing Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>8FD</scope><scope>FR3</scope><scope>P64</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>201111</creationdate><title>Functional factor VIII made with von Willebrand factor at high levels in transgenic milk</title><author>PIPE, S. W. ; MIAO, H. ; BUTLER, S. P. ; CALCATERRA, J. ; VELANDER, W. H.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5065-a671fd0857cff80824844a5620cc3ce4d48ee0b76df6bf4cdb37c86a753db7d93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Animals</topic><topic>Bioengineering</topic><topic>Cells, Cultured</topic><topic>Factor VIII - biosynthesis</topic><topic>Factor VIII - genetics</topic><topic>Factor VIII - therapeutic use</topic><topic>factor VIII</topic><topic>hemophilia</topic><topic>Hemophilia A - drug therapy</topic><topic>Humans</topic><topic>mammary gland</topic><topic>Mice</topic><topic>Mice, Transgenic</topic><topic>Milk - chemistry</topic><topic>Milk - metabolism</topic><topic>modified B domain</topic><topic>recombinant protein</topic><topic>transgenic animal</topic><topic>von Willebrand factor</topic><topic>von Willebrand Factor - biosynthesis</topic><topic>von Willebrand Factor - genetics</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>PIPE, S. W.</creatorcontrib><creatorcontrib>MIAO, H.</creatorcontrib><creatorcontrib>BUTLER, S. P.</creatorcontrib><creatorcontrib>CALCATERRA, J.</creatorcontrib><creatorcontrib>VELANDER, W. H.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of thrombosis and haemostasis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>PIPE, S. W.</au><au>MIAO, H.</au><au>BUTLER, S. P.</au><au>CALCATERRA, J.</au><au>VELANDER, W. H.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Functional factor VIII made with von Willebrand factor at high levels in transgenic milk</atitle><jtitle>Journal of thrombosis and haemostasis</jtitle><addtitle>J Thromb Haemost</addtitle><date>2011-11</date><risdate>2011</risdate><volume>9</volume><issue>11</issue><spage>2235</spage><epage>2242</epage><pages>2235-2242</pages><issn>1538-7933</issn><issn>1538-7836</issn><eissn>1538-7836</eissn><abstract>Background: Current manufacturing methods for recombinant human factor VIII (rFVIII) within mammalian cell cultures are inefficient, hampering the production of sufficient amounts for affordable, worldwide treatment of hemophilia A. However, rFVIII has been expressed at very high levels by the transgenic mammary glands of mice, rabbits, sheep, and pigs. Unfortunately, it is secreted into milk with low specific activity, owing in part to the labile, heterodimeric structure that results from furin processing of its B domain. Objectives: To express biologically active rFVIII in the milk of transgenic mice through targeted bioengineering. Methods: Transgenic mice were made with a mammary‐specific FVIII gene (226/N6) bioengineered for efficient expression and stability, encoding a protein containing a B domain with no furin cleavage sites. 226/N6 was expressed with and without von Willebrand factor (VWF). 226/N6 was evaluated by ELISA, SDS‐PAGE, western blot, and one‐stage and two‐stage clotting assays. The hemostatic activity of immunoaffinity‐enriched 226/N6 was studied in vivo by infusion into hemophilia A knockout mice. Results and conclusions: With or without coexpression of VWF, 226/N6 was secreted into milk as a biologically active single‐chain molecule that retained high specific activity, similar to therapeutic‐grade FVIII. 226/N6 had > 450‐fold higher IU mL−1 than previously reported in cell culture for rFVIII. 226/N6 exhibited similar binding to plasma‐derived VWF as therapeutic‐grade rFVIII, and intravenous infusion of transgenic 226/N6 corrected the bleeding phenotype of hemophilia A mice. This provides proof‐of‐principle for the study of expression of 226/N6 and perhaps other single‐chain bioengineered rFVIIIs in the milk of transgenic livestock.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>21920013</pmid><doi>10.1111/j.1538-7836.2011.04505.x</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1538-7933 |
ispartof | Journal of thrombosis and haemostasis, 2011-11, Vol.9 (11), p.2235-2242 |
issn | 1538-7933 1538-7836 1538-7836 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3444248 |
source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
subjects | Animals Bioengineering Cells, Cultured Factor VIII - biosynthesis Factor VIII - genetics Factor VIII - therapeutic use factor VIII hemophilia Hemophilia A - drug therapy Humans mammary gland Mice Mice, Transgenic Milk - chemistry Milk - metabolism modified B domain recombinant protein transgenic animal von Willebrand factor von Willebrand Factor - biosynthesis von Willebrand Factor - genetics |
title | Functional factor VIII made with von Willebrand factor at high levels in transgenic milk |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-16T11%3A57%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Functional%20factor%C2%A0VIII%20made%20with%20von%20Willebrand%20factor%20at%20high%20levels%20in%20transgenic%20milk&rft.jtitle=Journal%20of%20thrombosis%20and%20haemostasis&rft.au=PIPE,%20S.%20W.&rft.date=2011-11&rft.volume=9&rft.issue=11&rft.spage=2235&rft.epage=2242&rft.pages=2235-2242&rft.issn=1538-7933&rft.eissn=1538-7836&rft_id=info:doi/10.1111/j.1538-7836.2011.04505.x&rft_dat=%3Cproquest_pubme%3E1399903081%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1399903081&rft_id=info:pmid/21920013&rfr_iscdi=true |